Results for tag: "Rapastinel"

Rapastinel is a novel antidepressant drug developed by Allergan, a pharmaceutical company, for the treatment of major depressive disorder (MDD). It is a glutamate modulator, which works by targeting the N-methyl-D-aspartate (NMDA) receptor. Rapastinel has been shown to have a rapid onset of action, with some patients experiencing relief from symptoms within 24 hours. It is also thought to have fewer side effects than traditional antidepressants. Rapastinel is currently in Phase III clinical trials and is not yet approved by the US Food and Drug Administration (FDA). However, it has been granted Breakthrough Therapy Designation by the FDA, which could expedite its approval. The Rapastinel market is expected to grow in the coming years, as the drug could provide an effective and safe treatment option for MDD. It could also provide an alternative to traditional antidepressants, which have been associated with a range of side effects. Some of the companies in the Rapastinel market include Allergan, Lundbeck, and Otsuka Pharmaceuticals. Show Less Read more